No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

MicroVention Celebrates 25 Years in Neuroendovascular Technologies that Improve Patient Lives

Editor: What To Know

  • Founded in 1997 by a handful of Associates in a small facility in Southern California, MicroVention is now a worldwide community with over 3,000 Associates and distributors worldwide, operating in over 70 countries with offices across the United States, Europe, Asia, and Costa Rica.
  • Also, as part of the anniversary ceremonies, MicroVention will add to a time capsule that was built for the company’s 20-year anniversary in 2017 that was filled with various artifacts from the past 20 years of the company’s history.
  • Timothy White, a Neurosurgery Chief Resident and Endovascular Fellow at the Zucker School of Medicine at Hofstra Northwell, will provide an overview of a patient that was treated with MicroVention products.

MicroVention, Inc., a global neurovascular company and a wholly owned subsidiary of Terumo Corporation, celebrates its 25-year anniversary on September 29, 2022. Founded in 1997 by a handful of Associates in a small facility in Southern California, MicroVention is now a worldwide community with over 3,000 Associates and distributors worldwide, operating in over 70 countries with offices across the United States, Europe, Asia, and Costa Rica.

MicroVention has been focused on developing and marketing medical devices that improve patient lives through the treatment of strokes and aneurysms using our innovative products. In 2006, MicroVention was acquired by the Japan-based Terumo Corporation. Terumo provided the support for MicroVention to continue the culture of innovation and an entrepreneurial spirit.

MicroVention has launched over 30 products and has expanded beyond cerebral aneurysms to include treatment for ischemic stroke, carotid artery disease, and neurovascular malformations.

On MicroVention’s 25th anniversary, celebrations will occur across the globe that focus on its patients, product innovation, and its people – its Associates. The capstone of the anniversary celebration will include Patient’s Day. Dr. Timothy White, a Neurosurgery Chief Resident and Endovascular Fellow at the Zucker School of Medicine at Hofstra Northwell, will provide an overview of a patient that was treated with MicroVention products. Likewise, the patient will share her story of the positive impact and improvement of her life from being treated with multiple MicroVention products.

Also, as part of the anniversary ceremonies, MicroVention will add to a time capsule that was built for the company’s 20-year anniversary in 2017 that was filled with various artifacts from the past 20 years of the company’s history. The time capsule will be sealed and reopened in 2047 as a way of celebrating what the next 25 years may bring to the industry and company.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy